Develop and commercialize blood-based diagnostic tests for lung cancer. Offer the Nodify Lung Nodule Risk Assessment strategy to assess lung cancer risk. Now — the numbers.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
This grade is a blend: the profit side is strong, the sales tempo slow.
The stock has been running stronger than the market lately.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
An investor who bought at the very peak is down 85% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
We do not hold enough financial data on this company to point to a strength.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 22/100.
On our five-subject report card, BDSX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
One-line summary: few numbers, an untested story. Keep watching.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Not covered, because the filings we hold do not carry it: revenue and profit, the growth trend, the balance sheet, earnings execution, the revenue breakdown.